Medical AI

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

A new partnership between Hong Kong's PAIR and the UK's Cambridge NeuroWorks aims to accelerate brain health innovations through a global seminar series.

Industry veteran Steve Motes joins Tulyp Medical as CEO, aiming to commercialize a revolutionary pressure-driven perfusion system with a proven team.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

A startup's radical new model, born from a family's health crisis, directs all pediatric revenue to fund rare disease research and support families.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

FDA clears Allevion's Vantage™, a disposable kit with integrated visualization that targets bone growth, aiming to transform spinal decompression.

As maternity care deserts expand, one rural hospital is using wearable tech to bring vital prenatal monitoring to high-risk mothers right in their homes.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Neuroscientist-founded Steffie's launches wide-fit heels, blending sneaker tech with style to solve a problem millions of women face. Is this the future?

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A new partnership model merges virtual nephrology, clinical trials, and real-world data, aiming to empower independent doctors and improve patient access.